European Union - English - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - lutetium (177lu) chloride, quantity: 10 gbq/ml - solution - excipient ingredients: dilute hydrochloric acid; purified water - lutetium (177lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients. for the treatment of non resectable or metastatic neuroendocrine tumours (nets) expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

European Union - English - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - endolucinbeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

European Union - English - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lumark is a radiopharmaceutical precursor. it is not intended for direct use in patients. this medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.

Israel - English - Ministry of Health

novartis israel ltd - lutetium (177lu) vipivotide tetraxetan - solution for injection / infusion - lutetium (177lu) vipivotide tetraxetan 1000 mbq/ml - lutetium (177lu) vipivotide tetraxetan - pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

Singapore - English - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - lutetium (177lu) chloride - solution - lutetium (177lu) chloride 40 gbq/ml

Israel - English - Ministry of Health

s.r.y. (medical services ) ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 600 mbq/ml - lutetium (177lu) oxodotreotide - for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep-nets) in adults.

Israel - English - Ministry of Health

novartis israel ltd - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - lutetium (177lu) oxodotreotide - solution - 370mbq - lutetium (177lu) oxodotreotide 370mbq - antineoplastic agents

Israel - English - Ministry of Health

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - solution for infusion - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide - lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (g1 and g2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (gep nets) in adults.